Savient Delays 10-Q Filing Due To Oxandrin Return Reserve Errors
This article was originally published in The Pink Sheet Daily
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.
You may also be interested in...
"Significant enhancements" in commercial operations and business development organizations will allow King to grow as a standalone company, the firm says. Mylan and King announce termination of their proposed merger one day before the "walk-away" date.
Savient Pharmaceuticals has tapped President & Chief Operating Officer Christopher Clement as CEO following the retirement of Sim Fass.
FDA approves bisphosphonate line extension featuring four days of risedronate dosing and 24 days of calcium supplementation.